吉林敖东子公司获中药配方颗粒备案，政策利好促业务拓展

Group 1 - Jilin Aodong's subsidiary Yanbian Pharmaceutical has obtained 10 listings for traditional Chinese medicine formula granules, bringing the total to 535, which is expected to expand the company's business and enhance its core competitiveness [1] - The Ministry of Industry and Information Technology and seven other departments issued the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to cultivate raw material bases and promote industrial upgrades, providing policy benefits for traditional Chinese medicine companies [1] Group 2 - As of February 12, 2026, Jilin Aodong's stock price closed at 18.81 yuan, down 0.48% for the day, with a trading volume of 180 million yuan; net outflow of main funds was 35.58 million yuan, accounting for 19.8% of total trading volume [2] - Over the past five days, the stock price has decreased by 0.69%, and technical indicators show the stock is near the lower Bollinger Band at a support level of 18.21 yuan, indicating overall performance is weaker than the industry average [2]